Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy - Trial NCT03960151
Access comprehensive clinical trial information for NCT03960151 through Pure Global AI's free database. This Phase 2 trial is sponsored by Costantine Albany and is currently Withdrawn. The study focuses on Germ Cell Tumor. Target enrollment is 0 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Costantine Albany
Hoosier Cancer Research Network
Timeline & Enrollment
Phase 2
May 01, 2018
Mar 01, 2022
Primary Outcome
Complete Response Rate
Summary
Phase II study of Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone in patients
 with germ cell tumors undergoing 5-day Cisplatin-based chemotherapy
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03960151
Non-Device Trial